The collapse of Silicon Valley Bank will leave early-stage biotechnology companies with a funding void, investors and analysts said on Monday, but larger, publicly-traded drug companies should. | March 13, 2023
The collapse of Silicon Valley Bank will leave early stage biotechnology companies with a funding void, investors and analysts said on Monday, but larger, publicly traded drug companies should escape unscathed.